Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-04-02 Omalizumab/ Tezepelumab
| Omalizumab |
|
Formulary
|
Xolair® 75mg solution for injection in pre-filled syringe, 150mg solution for injection in pre-filled syringe Severe persistent allergic asthma in people aged 6 years and older (NICE TA278) |
 MHRA: Omalizumab: potential risk of arterial thrombotic events NICE TA278: Omalizumab for treating severe persistent allergic asthma |
|
| Tezepelumab |
|
Formulary
|
Tezspire® 210mg solution for injection in pre-filled pen, 210mg soultion for injection in pre-filled syringe |
|
NICE TA880 Tezepelumab for treating severe asthma |
|
|
| Omalizumab |
|
Formulary
|
Xolair® 75mg solution for injection in pre-filled syringe, 150mg solution for injection in pre-filled syringe |
|
MHRA: Omalizumab: potential risk of arterial thrombotic events NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) |
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- BNF: Antihistamines, allergen immunotherapy and allergic emergencies
- LSCMMG: Asthma Treatment Guideline for Adults
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: Chronic Obstructive Pulmonary Disease (COPD) Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA278: Omalizumab for treating severe persistent allergic asthma
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA479: Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA671: Mepolizumab for treating severe eosinophilic asthma
- NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
- NICE TA769: Palforzia for treating peanut allergy in children and young people
- NICE TA880 Tezepelumab for treating severe asthma